BusinessRespireRx Pharmaceuticals Inc. Announces Publication of Phase 2B PACE Study: Once per Night Treatment with Dronabinol Provides Statistically Significant Improvement in Clinical Measures of Obstructive Sleep ApneaBy Nasdaq OMXNov 30, 2017, 1:45 PM UTC
